Goldman Sachs’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Goldman Sachs’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$866K	–	6460
2020 Q4	$866K	Buy	+20,000	New	+$986K	﹤0.01%	4284
2020 Q2	–	Sell	-74,500	Closed	-$3.81M	–	5579
2020 Q1	$3.81M	Buy	74,500 +62,100	+501%	+$4.16M	﹤0.01%	2857
2019 Q4	$986K	Buy	+12,400	New	+$735K	﹤0.01%	4141
2018 Q3	–	Sell	-200	Closed	-$9K	–	5866
2018 Q2	$9K	Sell	200 -19,800	-99%	-$902K	﹤0.01%	5550
2018 Q1	$966K	Sell	20,000 -6,000	-23%	-$335K	﹤0.01%	4069
2017 Q4	$1.02M	Buy	+26,000	New	+$971K	﹤0.01%	4309
2016 Q2	–	Sell	-500,000	Closed	-$7.93M	–	7330
2016 Q1	$7.93M	Buy	+500,000	New	+$8.88M	﹤0.01%	2399

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's GBT Position: Q4 2022 in Review

Goldman Sachs sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,706,600 shares — an estimated $116M sold.

Goldman Sachs first reported a position in GBT in Q3 2015 and held it in 28 quarters. The position peaked at $116M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Goldman Sachs reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 1,706,600 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $116M.
Goldman Sachs first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 28 quarters.
Goldman Sachs's Global Blood Therapeutics, Inc. position peaked at $116M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.